157 related articles for article (PubMed ID: 19302283)
1. Multicolor in vivo targeted imaging to guide real-time surgery of HER2-positive micrometastases in a two-tumor coincident model of ovarian cancer.
Longmire M; Kosaka N; Ogawa M; Choyke PL; Kobayashi H
Cancer Sci; 2009 Jun; 100(6):1099-104. PubMed ID: 19302283
[TBL] [Abstract][Full Text] [Related]
2. Multi-targeted multi-color in vivo optical imaging in a model of disseminated peritoneal ovarian cancer.
Kosaka N; Ogawa M; Longmire MR; Choyke PL; Kobayashi H
J Biomed Opt; 2009; 14(1):014023. PubMed ID: 19256711
[TBL] [Abstract][Full Text] [Related]
3. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
Terwisscha van Scheltinga AG; van Dam GM; Nagengast WB; Ntziachristos V; Hollema H; Herek JL; Schröder CP; Kosterink JG; Lub-de Hoog MN; de Vries EG
J Nucl Med; 2011 Nov; 52(11):1778-85. PubMed ID: 21990576
[TBL] [Abstract][Full Text] [Related]
4. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
[TBL] [Abstract][Full Text] [Related]
5. Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases.
Ogawa M; Kosaka N; Longmire MR; Urano Y; Choyke PL; Kobayashi H
Mol Pharm; 2009; 6(2):386-95. PubMed ID: 19718793
[TBL] [Abstract][Full Text] [Related]
6. The use of fluorescent proteins for developing cancer-specific target imaging probes.
McCann TE; Kosaka N; Choyke PL; Kobayashi H
Methods Mol Biol; 2012; 872():191-204. PubMed ID: 22700412
[TBL] [Abstract][Full Text] [Related]
7. HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab.
Fujimura M; Katsumata N; Tsuda H; Uchi N; Miyazaki S; Hidaka T; Sakai M; Saito S
Jpn J Cancer Res; 2002 Nov; 93(11):1250-7. PubMed ID: 12460467
[TBL] [Abstract][Full Text] [Related]
8. Intraoperative imaging of metastatic lymph nodes using a fluorophore-conjugated antibody in a HER2/neu-expressing orthotopic breast cancer mouse model.
Wu J; Ma R; Cao H; Wang Z; Jing C; Sun Y; Zhang Y; Yang Z; Hoffman RM; Tang J
Anticancer Res; 2013 Feb; 33(2):419-24. PubMed ID: 23393332
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
Jiang D; Im HJ; Sun H; Valdovinos HF; England CG; Ehlerding EB; Nickles RJ; Lee DS; Cho SY; Huang P; Cai W
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1296-1305. PubMed ID: 28265738
[TBL] [Abstract][Full Text] [Related]
11. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
[TBL] [Abstract][Full Text] [Related]
12. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
[TBL] [Abstract][Full Text] [Related]
13. NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer.
Godard A; Kalot G; Privat M; Bendellaa M; Busser B; Wegner KD; Denat F; Le Guével X; Coll JL; Paul C; Bodio E; Goze C; Sancey L
J Med Chem; 2023 Apr; 66(7):5185-5195. PubMed ID: 36996803
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
Barok M; Tanner M; Köninki K; Isola J
Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
[TBL] [Abstract][Full Text] [Related]
15. Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu.
Koyama Y; Hama Y; Urano Y; Nguyen DM; Choyke PL; Kobayashi H
Clin Cancer Res; 2007 May; 13(10):2936-45. PubMed ID: 17504994
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
[TBL] [Abstract][Full Text] [Related]
17. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
[TBL] [Abstract][Full Text] [Related]
18. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.
Mitra D; Brumlik MJ; Okamgba SU; Zhu Y; Duplessis TT; Parvani JG; Lesko SM; Brogi E; Jones FE
Mol Cancer Ther; 2009 Aug; 8(8):2152-62. PubMed ID: 19671734
[TBL] [Abstract][Full Text] [Related]
19. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
Faratian D; Zweemer AJ; Nagumo Y; Sims AH; Muir M; Dodds M; Mullen P; Um I; Kay C; Hasmann M; Harrison DJ; Langdon SP
Clin Cancer Res; 2011 Jul; 17(13):4451-61. PubMed ID: 21571868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
